Mantle gell lymphoma: Glinicopathologic features and treatments

ONCOLOGY

Volumn 17, Issue 6, 2003, Pages 879-896

  Baidas, Said M ^a   Ciieson, Bruce D ^a   Kauh, John ^b   Ozdemirli, Metin ^b  

^a Department of Medicine and Oncology ^*

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

CHROMOSOME 11; CHROMOSOME 14; DIFFERENTIAL DIAGNOSIS; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOPHENOTYPING; MANTLE CELL LYMPHOMA; PATHOLOGY; PROGNOSIS; REVIEW; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, MANTLE-CELL; PROGNOSIS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 0041851015     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994. (Pubitemid 24273002)
2. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
3. Campo E, Raffeid M, Jaffe ES: Mantlecell lymphoma. Semin Hematol 36:115-127, 1999.
4. Weisenburger DD, Vose JM, Greiner TC, et al: Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000. (Pubitemid 30409035)
5. Jaffe ES, Campo E, Raffeid M: Mantle Cell Lymphoma: Biology and Diagnosis, pp 319-325. American Society of Hematology Educational Book, 1999.
6. Jaffe ES, Stein H, Vardiman JW, et al (eds): World Health Organization Classification of Tumors: Pathology, and Genetics of Hematopoietic Lymphoid Tissues, pp 168-170. Washington, DC, IARC Press, 2001.
7. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995.
8. Samaha H, Dumontet C, Ketterer N, et al: Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 12:1281-1287, 1998. (Pubitemid 28395993)
9. Cohen PL, Kurtin PJ, Donovan KA, et al: Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 101:302-310, 1998. (Pubitemid 28261118)
10. Pittaluga S, Verhoef G, Criel A, et al: Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 21:115-125, 1996. (Pubitemid 26059012)
11. Ott MM, Helbing A, Ott G, et al: Bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol 179:238-242, 1996. (Pubitemid 26266399)
12. Belaud-Rotureau MA, Parrens M, Dubus P, et al: A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol 15:517-525, 2002. (Pubitemid 34521400)
13. Elnenaei MO, Jadayel DM, Matutes E, et al: Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies. Leuk Res 25:115-123, 2001. (Pubitemid 32141114)
14. Bosch F, Jares P, Campo E, et al: PRAD1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726-2732, 1994. (Pubitemid 24317406)
15. Bigoni R, Negrini M, Veronese ML, et al: Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 13:797-802, 1996. (Pubitemid 26312907)
16. Bigoni R, Cuneo A, Milani R, et al: Secondary chromosome changes in mantle cell lymphoma: Cytogenetic and fluorescence in situ hybridization studies. Leuk Lymphoma 40:581-590, 2001. (Pubitemid 32303248)
17. Bea S, Ribas M, Hernandez JM, et al: Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365-4374, 1999. (Pubitemid 29279280)
18. Camacho E, Hernandez L, Hernandez S, et al: ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99:238-244, 2002.
19. Hofmann WK, de Vos S, Tsukasaki K, et al: Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98:787-794, 2001.
20. Gronbaek K, Nedergaard T, Andersen MK, et al: Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 12:12661271, 1998. (Pubitemid 28395990)
21. Garcia-Conde J, Cabanillas F: Mantle cell lymphoma: A lymphoproliferative disorder associated with aberrant function of the cell cycle. Leukemia (10 suppl 2):s78-83, 1996. (Pubitemid 126754015)
22. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994.
23. Chiarle R, Budel LM, Skolnik J, et al: Increased proteasome degradation of cyclindependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619-626, 2000. (Pubitemid 30041678)
24. Press OW, Fisher RI: Evaluation and management of mantle cell lymphoma. Adv Leuk Lymphoma 6:3-11, 1996.
25. Majlis A, Pugh WC, Rodriguez MA, et al: Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 15:1664-1671, 1997. (Pubitemid 27167407)
26. Fisher RI: Mantle Cell Lymphbma: Prognostic Factors and Treatment Results, pp 325-328. American Society of Hematology Educational Book, 1999.
27. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997. (Pubitemid 27132123)
28. Izban KF, Alkan S, Singleton TP, et al: Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAFl, p27KIPl, and p53 in mantle cell lymphoma. Arch Pathol Lab Med 124:1457-1462, 2000. (Pubitemid 30802493)
29. Raty R, Franssila K, Joensuu H, et al: Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69:11-20, 2002. (Pubitemid 35155435)
30. Pinyol M, Hernandez L, Cazorla M, et al: Deletions and loss of expression of p16INK4a and p21Wafl genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997. (Pubitemid 26428202)
31. Louie DC, Offit K, Jaslow R, et al: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32). Blood 86:2892-2899, 1995.
32. Garand R, Orchard JA, Davis Z, et al: A subset of mantle cell lymphoma exhibits stable disease and correlates with mutated VH genes and low CD 38 expression (abstract 3020). Blood 98:724a, 2001. (Pubitemid 33790279)
33. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998. (Pubitemid 28112997)
34. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995.
35. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998. (Pubitemid 28135602)
36. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998. (Pubitemid 29001533)
37. Oinonen R, Franssila K, Teerenhovi L, et al: Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients. Eur J Cancer 34:329-336, 1998. (Pubitemid 28183829)
38. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995.
39. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocyte lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989. (Pubitemid 19213752)
40. Hiddemann W, Unterhalt M, Herrmann R, et al: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930, 1998.
41. Zueca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995.
42. Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: A het-erogeneous group of patients with distinct clinical features and outcome. Blood 83:2829-2835, 1994. (Pubitemid 24142713)
43. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al: The clinical outcome of 65 cases of mantle cell lymphoma initially treated with nonintensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 99:842-847, 1997. (Pubitemid 28047149)
44. Gressin R, Legouffe E, Leroux D, et al: Treatment of mantle-cell lymphomas with the VAD ± chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Ann Oncol (8 suppl 1):103-106, 1997. (Pubitemid 27239441)
45. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999. (Pubitemid 29075241)
46. Zinzani PL, Magagnoli M, Moretti L, et al: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 18:773-779, 2000. (Pubitemid 30106607)
47. Weisenburger DD, Vose JM, Greiner TC, et al: Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000. (Pubitemid 30409035)
48. Connors JM, Kouroukis C, Belch A: Flavopiridol for mantle cell lymphoma: Moderate activity and frequent disease stabilization (abstract 3355). Blood 98:807a, 2001. (Pubitemid 33790614)
49. Inwards D, Brown D, Fonseca R, et al: NCCTG phase II trial of 2-chIorodeoxyadenosine as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity (abstract 2930). Blood 94:660a, 1999.
50. Poynton C, Maughan T, Hasan F: Topotecan in mantle cell lymphoma-A 21 day continuous infusion regimen may have advantages over intermittent therapy (abstract 4711 ). Blood 98:245b, 2001.
51. Seymour JF, Grigg AP, Szer J, et al: Cisplatin, fludarabine, and cytarabine: A novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 94:585-593, 2002. (Pubitemid 34132284)
52. Unterhalt M, Herrmann R, Tiemann M, et al: Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 10:836-843, 1996. (Pubitemid 26168402)
53. Shah P, Ifthikharuddin J, Mintz M: 2-Chlorodeoxyadenosine (2-CDA) with weekly rituximab and granulocyte-macrophage colony stimulating factor (GM-CSF): A highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD) (abstract 4726). Blood 98:249b, 2001.
54. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998.
55. Coiffier B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 29(1 suppl 2):30-35, 2002. (Pubitemid 34171792)
56. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000. (Pubitemid 30056420)
57. Ghielmini M, Schmitz SF, Burki K, et al: The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol(11 suppl 1): 123-126, 2000.
58. Nguyen DT, Amess JA, Doughty H, et al: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade nonHodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62:76-82, 1999. (Pubitemid 29071265)
59. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002.
60. Hiddemann W, Unterhalt M, Dreylin M: The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG) (abstract 339). Blood 100:92a, 2002.
61. Drach J, Kaufman H, Puespoek A: Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma (abstract 606). Blood 100:162a, 2002.
62. Venugopal P, Woolridge JE, Yunus F: Phase II study of rituximab in combination with CHOP chemotherapy and GMCSF (Leukine) in patients with previously untreated diffuse large cell lymphoma (DLCL) and mantle cell lymphoma (MCL) (abstract 4736). Blood 98:251b, 2001.
63. Levine A, Espina BM, Mohrbacher A: Fludarabine, mitoxantrone, and rituxan: An effective regimen for the treatment of mantle cell lymphoma (abstract 1399). Blood 100:361a, 2002.
64. Wilson W, Neelapu S, White T: Idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma (abstract 608). Blood 100:162a, 2002.
65. Romaguera J, Cabanillas F, Dang N: Mantle cell lymphoma (MCL)-High rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT) (abstract 3030). Blood 98:726a, 2001. (Pubitemid 33790289)
66. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000. (Pubitemid 30616849)
67. Oinonen R, Jantunen E, Itala M, et al: Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymphoma 43:1229-1237, 2002.
68. Mangel J, Buckstein R, Imrie K, et al: Immunotherapy with rituximab following highdose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 29(1 suppl 2):56-69, 2002. (Pubitemid 34171796)
69. Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and antiB-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 16:13-18, 1998. (Pubitemid 28041573)
70. Stewart DA, Vose JM, Weisenburger DD, et al: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6:263-266, 1995.
71. Haas R, Brittinger G, Meusers P, et al: Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lym-phoma. Leukemia 10:1975-1979, 1996.
72. Dreger P, von Neuhoff N, Kuse R, et al: Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 8:401-403, 1997. (Pubitemid 27230983)
73. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002. (Pubitemid 34525293)
74. Molina A, Kraft D, Carter N, et al: Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL): A report of 69 patients from City of Hope (COH) and Stanford (abstract 680). Blood 100:182a, 2002.
75. Milpied N, Gaillard F, Moreau P, et al: High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience. Bone Marrow Transplant 22:645-650, 1998. (Pubitemid 28486362)
76. Decaudin D, Brousse N, Brice P, et al: Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3-year followup study. Bone Marrow Transplant 25:251-256, 2000. (Pubitemid 30103013)
77. Ketterer N, Salles G, Espinouse D, et al: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 8:701-704, 1997. (Pubitemid 27372172)
78. Blay JY, Sebban C, Surbiguet C, et al: High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: A single center experience on 18 patients. Bone Marrow Transplant 21:51-54, 1998: (Pubitemid 28043436)
79. Kroger N, Hoffknecht M, Dreger P, et al: Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21:55-57, 1998. (Pubitemid 28043437)